

International Conference on
Pathology and Infectious Diseases
&
3rd International Conference on
Pathology and Oncology Research

November 11-12, 2019 | Singapore



Sidharth Sonthalia

SKINNOCENCE: The Skin Clinic and Research Centre, India

THE AZOLE MENACE: The dark side of azoles revealed

Background: The Epidemic of antifungal therapeutic failures against superficial mycotic infections, especially dermatophytosis is expanding at a rapid pace across South Asia and beyond. Although the abuse of topical steroids, inadequate dose/duration of therapy, and ignorance of other important epidemiological and personal factors are contributory, perhaps the strongest reason is the AZOLE MENACE, relatively unknown and ill-understood phenomenon. In this lecture, I shall dwell upon objectively on how the indiscriminate use of azoles, in particular, oral itraconazole is responsible for this regional epidemic that is threatening to become a pandemic lest urgent rectification is undertaken.

Unknown Facts Revealed: In this lecture some of the many azole-related issues will be revealed with evidence-backed data.

- Patients with tinea visiting a dermatologist are not naive, rather polypharmacy-abused in more than 90% cases, having received multiple antifungals especially oral itraconazole/topical azoles.
- Oral itraconazole is often injudiciously prescribed by primary care physicians in an inadequate dose/ duration or as multiple intermittent/ prolonged courses.

The bioavailability/ serum levels of itraconazole are influenced by at least 15+ inconsistent factors

- Around 54.3% Indians above the age of 45 years are on antacid medications like PPI's, resulting in reduced bioavailability of itraconazole when co-administered. The effects of longer acting PPI's like esomeprazole may persist up to 4-5 days.
- Dependent on intake post meals and the effect of aerated drinks.
- Serum levels affected by drug brand and pellet size.
- The sub-inhibitory concentrations of itraconazole achieved in patient's serum significantly increase the likelihood of

secondary azole resistance by selection pressure, since azoles being fungistatic allow persistence of organisms.

- The selection pressure-induced secondary resistance resulting from oral itraconazole is also seen to perpetuate pan-triazole and partial terbinafine and amorolfine resistance. Ciclopirox olamine is the only drug without a propensity to develop resistance.
- Itraconazole-resistant strains show high levels of cross-resistance to multiple triazoles including voriconazole and posaconazole, and often to six triazole fungicides used extensively in agriculture, qualifying for multi-triazole resistance).
- Azole-resistant fungi are more virulent because of the differences in cell wall composition, increased filamentation and adherence, and enhanced biofilm formation. Once acquired, resistance is maintained even in the absence of drug.
- Primary azole resistance due to their widespread use as agricultural fungicides, further adds to the azole menace. This phenomenon, which started from the Netherlands and rapidly engulfed majority of the European Union, has now reached the shores of the Indian Ocean. As per the statistics available from the website of Indian Ministry of Agriculture, in the 4-year period from 2012 to 2016, there was an estimated 29.5% decrease and 34.2% increase in the consumption of insecticides and fungicides respectively.
- The spreading azole resistance in superficial fungal infections resulting in selection of a population of mutants that don't respond to any drug is likely to have graver ramifications in invasive dermatophytosis in immunocompromised individuals.

Practical Guidelines to contain & reverse the epidemic:

- Majority of patients with complicated tinea (recurrent/relapsed/recalcitrant/chronic) who visit dermatologists have already taken multiple/prolonged courses of oral itraconazole, rendering them resistant to any further course of itraconazole; thus, they should not be given oral itraconazole.
- Resistance to terbinafine on the other hand, acquired through a rare mechanism, is infrequent, shows restoration of

International Conference on
Pathology and Infectious Diseases
&
3rd International Conference on
Pathology and Oncology Research

November 11-12, 2019 | Singapore

susceptibility after drug removal and has not been reported to confer cross-resistance to other antifungal agents.

- The dosing of oral TERBINAFINE should be as per body weight, 6mg/kg/day and it should be given for a duration of 8 (minimum) to 12 weeks (preferred), taking into consideration the dermatophytic involvement of vellus hair.
- For topical application, NO AZOLES should be used. Only three anti-fungals seem fit for topical use in current scenario – CICLOPIROX > TERBINAFINE > AMOROLFINE.
- Non-pharmaceutical means, such as low-dose UV-B therapy, LLLT, apple cider vinegar and other herbal substances capable of breaking the BIOFILM should be used as adjuvants.

Speaker Biography

Sidharth Sonthalia is a Senior Consultant Dermatologist & Medical Director, SKINNOCENCE: The Skin Clinic & Research Center, Gurugram, India. He devotes his time equally to patients, active research (translational/clinical) and education of other Dermatologists and allied Specialists in novel and controversial subjects like Dermoscopy, Dermatopathology, Management of Resistant Fungal Infections, Psychodermatology PCOS etc., by organizing focused congresses and International Summits under the aegis of his initiative DermaSource India,. He has delivered more than 80 lectures as invited Guest Faculty at various International conferences organized by ASPCR, ICD, IPCC, CCD, WCD, WDC and DERMACONS. He is serving as the Founding Chair of the South Asian Alliance against Cutaneous Mycosis [SAARCUM], Secretary General of Asian Society of Pigment Cell research [ASPCR], Chief Founder & Secretary General of the Indian Society of Dermoscopy, Onychoscopy & Trichoscopy [ISODOT], He is a founding co-chair of the Afro-Asian Dermoscopy Group [AADG].

e: drsidharthsonthalia@gmail.com